B. Riley Comments on InfuSystem’s Q2 Earnings (NYSE:INFU)

InfuSystem Holdings, Inc. (NYSE:INFU) – Equities research analysts at B. Riley cut their Q2 2025 EPS estimates for InfuSystem in a note issued to investors on Tuesday, March 4th. B. Riley analyst K. Bauser now anticipates that the company will post earnings per share of $0.05 for the quarter, down from their previous estimate of $0.06. The consensus estimate for InfuSystem’s current full-year earnings is $0.15 per share. B. Riley also issued estimates for InfuSystem’s FY2025 earnings at $0.23 EPS.

Separately, StockNews.com upgraded shares of InfuSystem from a “buy” rating to a “strong-buy” rating in a report on Friday, November 8th.

InfuSystem Stock Performance

INFU stock opened at $6.23 on Thursday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.59 and a current ratio of 1.98. The stock has a market cap of $132.47 million, a P/E ratio of 103.85 and a beta of 1.75. The firm has a 50 day simple moving average of $8.00 and a 200 day simple moving average of $7.61. InfuSystem has a 52 week low of $5.74 and a 52 week high of $9.97.

Institutional Trading of InfuSystem

Institutional investors have recently added to or reduced their stakes in the business. Oppenheimer Asset Management Inc. lifted its stake in InfuSystem by 28.0% in the third quarter. Oppenheimer Asset Management Inc. now owns 33,337 shares of the company’s stock valued at $223,000 after acquiring an additional 7,295 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in InfuSystem by 66.4% in the third quarter. BNP Paribas Financial Markets now owns 4,076 shares of the company’s stock valued at $27,000 after acquiring an additional 1,626 shares during the last quarter. Barclays PLC lifted its stake in InfuSystem by 300.5% in the third quarter. Barclays PLC now owns 28,597 shares of the company’s stock valued at $192,000 after acquiring an additional 21,457 shares during the last quarter. Geode Capital Management LLC lifted its stake in InfuSystem by 1.8% in the third quarter. Geode Capital Management LLC now owns 436,508 shares of the company’s stock valued at $2,925,000 after acquiring an additional 7,550 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in InfuSystem by 74.1% in the third quarter. JPMorgan Chase & Co. now owns 15,556 shares of the company’s stock valued at $104,000 after acquiring an additional 6,623 shares during the last quarter. 71.13% of the stock is currently owned by institutional investors and hedge funds.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.